Peter Lynch · Growth at a reasonable price (GARP)
Is ACADIA Pharmaceuticals Inc. (ACAD) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
71/100
Mixto
4/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a ACAD
PEG ≤ 1.0
clave-
EPS CAGR ≥ 15%
clave-
Revenue CAGR ≥ 10%
22.0%
Net margin > 0
34.3%
Cómo se valora ACAD en otras estrategias
Datos financieros en vivo
Cap. mercado
$3.44B
PER (TTM)
9.6x
ROIC (TTM)
6.17%
Margen bruto
91.47%
Otros análisis Peter Lynch
Preguntas frecuentes
What is ACAD's Peter Lynch fit score?
ACAD scores 71/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own ACAD?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ACAD.
How often is this score updated?
ACAD's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende ACAD personalmente.
